clinical trial · NCT03274479
PBF-1129 in Patients With NSCLC
Locally Advanced or Metastatic NSCLCPBF-1129
brief summary
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.
started
Oct 1, 2018
primary completion
May 1, 2024
completion
Aug 1, 2024
last updated
Feb 9, 2024
official title
Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol